Literature DB >> 14993932

The Rho-ROCK system as a new therapeutic target for preventing interstitial fibrosis.

Toshiki Moriyama1, Katsuyuki Nagatoya.   

Abstract

The small GTPase Rho is involved in cell-to-substratum adhesion and cell contraction. These actions of Rho mediated by downstream Rho effectors such as Rho-associated coiled-coil forming protein kinase (ROCK) may be partly responsible for the progression of renal interstitial fibrosis. A body of evidence has been accumulated with regard to the involvement of the Rho-ROCK signaling pathway in the development of fibrotic lesions in various organs including the kidney. Tubulointerstitial fibrosis is a final common pathway to the eventual structural desolation of kidneys, and therefore is an important therapeutic target to cure or reverse the progressive functional deterioration. In this review, we will highlight the possible involvement of the Rho-ROCK signaling pathway in the pathogenesis of tubulointerstitial fibrosis and discuss the therapeutic approach toward tubulointerstitial fibrosis by the inhibition of the Rho-ROCK pathway. (c) 2004 Prous Science. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14993932     DOI: 10.1358/dnp.2004.17.1.829023

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  15 in total

1.  Hierarchy of molecules in TGF-β1 signaling relevant to myofibroblast activation and renal fibrosis.

Authors:  Ming Zhan; Yashpal S Kanwar
Journal:  Am J Physiol Renal Physiol       Date:  2014-06-25

2.  Rho/Rock cross-talks with transforming growth factor-β/Smad pathway participates in lung fibroblast-myofibroblast differentiation.

Authors:  Hong Ji; Haiying Tang; Hongli Lin; Jingwei Mao; Lili Gao; Jia Liu; Taihua Wu
Journal:  Biomed Rep       Date:  2014-07-31

Review 3.  Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research.

Authors:  Ponugoti Vasantha Rao; Padmanabhan P Pattabiraman; Casey Kopczynski
Journal:  Exp Eye Res       Date:  2016-09-01       Impact factor: 3.467

4.  RhoA GTPase-induced ocular hypertension in a rodent model is associated with increased fibrogenic activity in the trabecular meshwork.

Authors:  Padmanabhan P Pattabiraman; Tommy Rinkoski; Eric Poeschla; Alan Proia; Pratap Challa; Ponugoti V Rao
Journal:  Am J Pathol       Date:  2014-12-12       Impact factor: 4.307

5.  Leptin induces phagocytosis of apoptotic bodies by hepatic stellate cells via a Rho guanosine triphosphatase-dependent mechanism.

Authors:  Joy X Jiang; Kenichiro Mikami; Vijay H Shah; Natalie J Torok
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

6.  Rho kinase-1 mediates cardiac fibrosis by regulating fibroblast precursor cell differentiation.

Authors:  Sandra B Haudek; Damon Gupta; Oliver Dewald; Robert J Schwartz; Lei Wei; JoAnn Trial; Mark L Entman
Journal:  Cardiovasc Res       Date:  2009-04-30       Impact factor: 10.787

7.  Leiomyoma cells in 3-dimensional cultures demonstrate an attenuated response to fasudil, a rho-kinase inhibitor, when compared to 2-dimensional cultures.

Authors:  Minnie Malik; Joy Britten; James Segars; William H Catherino
Journal:  Reprod Sci       Date:  2014-08-01       Impact factor: 3.060

Review 8.  The pericyte: cellular regulator of microvascular blood flow.

Authors:  Matthew E Kutcher; Ira M Herman
Journal:  Microvasc Res       Date:  2009-02-07       Impact factor: 3.514

Review 9.  Fibroblast activation and myofibroblast generation in obstructive nephropathy.

Authors:  María T Grande; José M López-Novoa
Journal:  Nat Rev Nephrol       Date:  2009-06       Impact factor: 28.314

10.  Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin.

Authors:  Marjan Boerma; Qiang Fu; Junru Wang; David S Loose; Alessandra Bartolozzi; James L Ellis; Sharon McGonigle; Elsa Paradise; Paul Sweetnam; Louis M Fink; Marie-Catherine Vozenin-Brotons; Martin Hauer-Jensen
Journal:  Blood Coagul Fibrinolysis       Date:  2008-10       Impact factor: 1.276

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.